The report examined the cost-effectiveness of Pfizer’s Paxlovid, Merck’s molnupiravir, GlaxoSmithKline and Vir’s sotrovimab and generic drug fluvoxamine, which has yet to receive approval from the FDA to treat COVID-19 but can be used off-label to treat the condition.
Sotrovimab had the highest cost per hospitalization averted at $91,000, and its cost per quality-adjusted life year was $69,000.
Molnupiravir’s cost per hospitalization averted was $63,000, and its cost per quality-adjusted life year was $55,000.
Paxlovid’s cost per hospitalization averted was $21,000, and its cost per quality-adjusted life year was $18,000.
Fluvoxamine cost per hospitalization averted was $7,000, and its cost per quality-adjusted life year was $6,000.
ICER considers anything below $100,000 per quality-adjusted life year to be cost-effective.
Read the full report here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.